Wellington Management Group LLP Sells 3,026 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wellington Management Group LLP cut its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 6.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,803 shares of the specialty pharmaceutical company’s stock after selling 3,026 shares during the quarter. Wellington Management Group LLP owned about 0.07% of Jazz Pharmaceuticals worth $5,148,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at $5,519,000. Allianz SE bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Cornercap Investment Counsel Inc. purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $518,000. Orion Portfolio Solutions LLC increased its stake in shares of Jazz Pharmaceuticals by 36.8% during the fourth quarter. Orion Portfolio Solutions LLC now owns 30,625 shares of the specialty pharmaceutical company’s stock valued at $3,771,000 after purchasing an additional 8,235 shares in the last quarter. Finally, New Age Alpha Advisors LLC purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $183,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $102.05 on Friday. The firm has a fifty day simple moving average of $130.10 and a two-hundred day simple moving average of $122.73. The firm has a market cap of $6.20 billion, a PE ratio of 14.37, a P/E/G ratio of 1.04 and a beta of 0.42. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on JAZZ shares. Piper Sandler restated an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Barclays reissued an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Royal Bank of Canada lowered their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. HC Wainwright increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $187.71.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,736 shares of company stock worth $4,023,305. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.